Back

Moderate-intensity statin combined with ezetimibe versus high-intensity statin monotherapy for secondary cardiovascular risk reduction: a systematic review and meta-analysis

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Novel and old treatments, evidence in large populations Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Mangesh Kritya

Inamdar Multispecialty Hospital, Pune (India)

7 More presentations in this session

Presentation thumbnail
Ezetimibe use and mortality after myocardial infarction: a nationwide cohort study
Doctor V. Kyto (Turku, FI)
Abstract Slides Video
Presentation thumbnail
Lipid-lowering therapy with Inclisiran in the real-world setting: initial data from a national health care service
Associate Professor B. Zafrir (Haifa, IL)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of intravenous iron therapy in heart failure patients with iron deficiency: a systematic review and meta-analysis of randomized controlled trials
Doctor M. Abouzid (Poznan, PL)
Abstract Slides Video
Presentation thumbnail
Prognostic implications of guideline-directed medical therapy in functional mitral regurgitation: a meta-analysis
Doctor V. Anastasiou (London, GB)
Abstract Slides Video
Presentation thumbnail
Temporal trends and regional differences of initial oral antiarrhythmic drug options in patients with new-onset atrial fibrillation: a report from the GLORIA-AF registry
Mr B. Huang (Chongqing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Novel and old treatments, evidence in large populations

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Safety and Efficacy of Moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease: a meta-analysis
thumbnail
Congress Presentation
Efficacy of combination therapy with statin and ezetimibe versus high dose statin monotherapy in secondary prevention in high-risk patients
thumbnail
Congress Presentation
Combination of moderate-intensity statins and ezetimibe versus high-intensity statins alone for primary prevention of cardiovascular events

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources